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Abstract
Unlike the proliferative action of other EGF receptor family members, HER4/ErbB4 is often
associated with growth inhibitory and differentiation signaling. These actions may involve HER4
two-step proteolytic processing by intra-membraneous γ-secretase, releasing the soluble,
intracellular 80kDa HER4 cytoplasmic domain, s80HER4. We demonstrate that pharmacologic
inhibition of either γ-secretase activity or HER4 tyrosine kinase activity blocked heregulin-
dependent growth inhibition of SUM44 breast cancer cells. We next generated breast cell lines
stably expressing GFP-s80HER4 (GFP fused to the N-terminus of the HER4 cytoplasmic domain,
residues 676–1308), GFP-CTHER4 (GFP fused to N-terminus of the HER4 C-terminus distal to the
tyrosine kinase domain, residues 989–1308) or GFP alone. Both GFP-s80HER4 and GFP-CTHER4
were found in the nucleus, but GFP-s80HER4 accumulated to a greater extent and sustained its
nuclear localization. s80HER4 was constitutively tyrosine phosphorylated and treatment of cells
with a specific HER family tyrosine kinase inhibitor i) blocked tyrosine phosphorylation; ii)
markedly diminished GFP-s80HER4 nuclear localization, and iii) reduced STAT5A tyrosine
phosphorylation and nuclear localization as well as GFP-s80HER4:STAT5A interaction. Multiple
normal mammary and breast cancer cell lines, stably expressing GFP-s80HER4 (SUM44, MDA-
MB-453, MCF10A, SUM102, and HC11) were growth inhibited compared to the same cell line
expressing GFP-CTHER4, or GFP alone. The s80HER4-induced cell number reduction was due to
slower growth, as rates of apoptosis were equivalent in GFP, GFP-CTHER4, and GFP-s80HER4
expressing cells. Lastly, GFP-s80HER4 enhanced differentiation signaling as indicated by
increased basal and prolactin-dependent β–casein expression. These results indicate that surface
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HER4 tyrosine phosphorylation and ligand-dependent release of s80HER4 are necessary, and
s80HER4 signaling is sufficient for HER4-dependent growth inhibition.
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INTRODUCTION
Drosophilia and C. elegans genomes encode a single EGF receptor-like molecule.
Depending upon the cellular context and the expression of ligand or other accessory
molecules, the single EGF receptor enhances cell proliferation or inhibits growth, and
stimulates differentiation (1). Mammalian genomes contain four members of this receptor
tyrosine kinase family: EGFR/HER1/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/
ErbB4. These four members, together with at least 10 ligands from two ligand families (the
EGF and heregulin/neuregulin families), regulate numerous cellular functions, the most
studied of which is proliferation but also include cell survival, motility, adhesion,
differentiation and cell cycle inhibition (2–6). This complexity is, in part, due to the multiple
ligands, which bind to receptors to produce receptor homodimers or heterodimers, with
virtually all potential combinations of the four receptors. These activated receptor
complexes stimulate well-known signaling cascades, including Ras-Raf MAP Kinase
pathway and the PI3 kinase pathway (2–6). However, multiple other signaling pathways
must be involved to achieve the diversity of biologic outcomes.
All four family members are expressed in breast epithelium and in many breast cancers. The
EGF receptor, HER2 and HER3, appear, in general, to be involved in breast epithelial cell
proliferation (3). In the mouse, the EGF receptor, HER2 and HER3, regulate mammary
epithelial cell proliferation during puberty, while HER4 is activated during late pregnancy
and lactation, and signals for differentiation (7–9). EGFR and HER2 have been studied
extensively in experimental breast cancer models, as well as in human breast cancer
samples. HER2 and EGFR overexpression or activation is associated with poor prognosis
breast cancer, and molecular therapies targeting EGFR or HER2 have gained attention and,
in some instances, success for the treatment of human breast cancer (3–5,10).
HER4 was the last member of the family identified (11) and its relationship to breast cancer
prognosis is still being defined (12). Most studies correlate HER4 expression with estrogen
receptor positivity, lower tumor grade, and a better prognosis (13–16), but some studies
report a poorer prognosis in subsets of HER4 positive breast cancers (17,18). Newer
findings regarding HER4 isoforms and their unique signaling and cellular processing may
eventually explain these discrepancies in clinical correlation. HER4 RNA is alternatively
spliced to yield four isoforms that may vary in signaling capability (19–21). Just proximal to
the transmembrane region, an alternative splice creates the JM-a or JM-b isoform. JM-a, but
not JM-b, is susceptible to proteolytic cleavage by tumor necrosis factor alpha converting
enzyme (TACE) (22,23). Several groups have shown that cleavage by TACE releases the
extracellular domain and leads to a stochastic, second intramembrane cleavage event,
performed by a γ-secretase-like molecule of the presenilin family (24,25). This type of
cleavage is characteristic of Notch, another transmembrane protein involved in growth and
differentiation signaling (24). TACE leaves a membrane-associated m80kDaHER4, while the
second, γ-secretase intramembraneous cleavage, releases the 80 kDa domain into the
cytoplasm. Once released, three canonical nuclear localization sequences (NLS) and three
nuclear export sequences (NES) can result in appearance of s80HER4 in the nucleus of tested
cells (25).
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Our group and others have shown that, in many HER4-expressing breast cells, heregulin
treatment inhibits cell growth and can induce differentiation (26–31). Data from genetically
engineered mice also suggests that HER4 is involved in mammary cell differentiation (9,32),
as mammary-specific HER4 gene deletion or inhibition by dominant negative HER4
expression retards mammary gland development and function. In contrast to studies
demonstrating HER4-dependent growth inhibition, some reports show that HER4 activation
can stimulate growth and cell survival (33–35), although several of these reports used other
HER4 isoforms that may have distinct properties. How HER4 proteolytic processing
impacts growth inhibition, differentiation, or proliferation signaling, and how it may relate
to tumor suppression progression, or prognosis remains to be fully elucidated.
Immunostaining, using C-terminus HER4 antibodies, reveals HER4 (presumably s80HER4)
in the nucleus of normal human and mouse mammary cells, and nuclear HER4 has been
detected by immunohistochemistry in breast cancer samples. In most, but not all, studies,
nuclear HER4 staining correlates with a better prognosis (16,36,37).
The initial reports describing the sequential cleavage of HER4 by TACE and γ–secretase
demonstrated its importance for growth inhibition of T47D breast cancer cells. But TACE
and γ–secretase have also been reported to involve the cleavage of a number of other
proteins including Notch (24), E-cadherin (38), CD44 (39), nectin-1α (40), and syndecan 3
(41), which may also influence mammary cells. Evidence of growth inhibition by the
s80HER4 Cyt1 isoform across a range of normal and neoplastic breast cells is still lacking. In
addition, several reports examining gene transactivation indicated that the HER4 C-terminus
(beyond the tyrosine kinase domain) (25,42) and the C-terminus of the EGF receptor (43) or
HER2 (44), when fused to GAL4 DNA binding domain, are capable of stimulating GAL4
transactivation. This leaves open the possibility that the distal C-terminus may be the active
moiety in nuclear HER4 signaling.
To further study the biologic signaling capabilities of the intracellular HER4 fragments, we
have stably introduced GFP-tagged s80HER4 or the GFP-tagged HER4 C-terminus (the last
320 amino acids) into multiple normal mammary epithelial cells and breast cancer cells. We
report that s80HER4 is constitutively tyrosine phosphorylated. In addition, the full
cytoplasmic domain, s80HER4, which is kinase active, but not the HER4 C-terminus,
inhibited cell proliferation, transactivated the promoter for the mammary specific gene, β-
casein, and increased basal and prolactin-dependent β-casein mRNA expression. s80HER4-
dependent growth inhibition was due to slower growth rather than apoptosis. s80HER4
accumulates in the nucleus to a greater extent than CTHER4, and inhibition of s80HER4
kinase activity diminished its nuclear localization and interaction with STAT5A, as well as
tyrosine phosphorylation and nuclear localization of STAT5A.
RESULTS
γ-secretase inhibition abolishes heregulin-dependent SUM44 cell growth inhibition
We previously showed that both heregulin and HB-EGF inhibited the growth of SUM44 and
other HER4-expressing breast cancer cells (31). Since SUM44 cells do not express EGFR
and selective loss of HER2, HER3 tyrosine phosphorylation does not block the growth
inhibitory action of ligand, HER4 is responsible for transmitting this signal (31,45).
However, because a unique cellular processing scheme for certain HER4 isoforms has been
described, the role of processing HER4 needs to be examined. This ligand-dependent, two-
step proteolytic process releases the 80 kDa HER4 intracellular domain (s80HER4) into the
cytoplasm. The cleavable isoform, JM-a, is expressed in SUM44 and could be subject to the
extracellular domain cleavage performed by a TACE-like activity (22,23,46), followed by a
second intramembranous cleavage, performed by a γ-secretase-like intramembraneous
enzyme (25,47). To determine if surface HER4 or intracellularly released s80HER4 is
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responsible for growth inhibition, we assessed whether HER4 cleavage and s80HER4
formation were required for this heregulin-dependent action. We first pre-incubated SUM44
with 100 nM HEDI, a commercially available γ-secretase inhibitor, for one hour prior to
adding heregulin (10 ng/ml). Heregulin treatment diminished the increase of SUM44 cell
number over a six-day culture period by approximately 50%; however, incubation with the
γ-secretase inhibitor abolished this anti-proliferative effect (Fig. 1). Similar results were
obtained by Carpenter and co-workers, using the γ-secretase inhibitor compound E in T47D
breast cancer cells (25). Thus, γ-secretase activity is necessary for heregulin-dependent
growth inhibition, but it remained formally possible that the γ-secretase activity blockade
inhibited another signaling pathway (e.g. Notch, E-cadherin, or syndecan 3 cleavage) and
not the HER4 cytoplasmic domain release.
Inhibition of HER4 tyrosine phosphorylation blocks the heregulin-dependent anti-
proliferative effect
The process by which s80HER4 formation is regulated by ligand is not fully elucidated.
Treatment of several cell lines with the phorbol ester, TPA, induces TACE-dependent HER4
extracellular domain cleavage, leaving the transmembrane anchor and a membrane-bound
80kDa HER4 (m80HER4) (22,48). This species, at some rate, is released as s80HER4 by γ-
secretase cleavage at a valine residue just inside the cytoplasmic membrane surface (25,47).
Presumably ligand-dependent (heregulin, HB-EGF, etc.), release of s80HER4 also requires
TACE activation, followed by γ-secretase cleavage. The ligand-dependent cleavage process
is either inefficient or subject to other control mechanisms, as ligand-dependent HER4
activation leaves the majority of HER4 at the cell surface as 180kDa holoenzyme for four or
more hours (data not shown). Thus, inhibition of HER4 tyrosine kinase activation could
block heregulin-dependent anti-proliferative effects, either by preventing ligand-dependent
s80HER4 release or by inhibiting a necessary, sustained tyrosine kinase-dependent HER4
action at the cell surface, or both.
We investigated the necessity of HER4 tyrosine kinase activation in growth inhibition by
incubating SUM44 cells for 60 minutes with the pan-EGF receptor family inhibitor,
GW572016 (lapatinib), prior to addition of heregulin. In SUM44 cells (which do not express
the EGF receptor), incubation with increasing doses of GW572016 resulted in inhibition of
heregulin-dependent tyrosine phosphorylation of HER2, HER3 and HER4, all at similar
doses, with near-maximal inhibition at 1.0 μM (Fig. 2A). This dose was used in SUM44
growth studies, and experiments demonstrated that 1.0 μ GW572016, incubated with cells
for six days, nearly abolished heregulin-dependent growth inhibition (Fig. 2B). Taken with
previous findings that HER4 homodimers mediate heregulin-induced growth inhibition,
these results suggest that HER4 tyrosine phosphorylation is necessary for the growth
inhibitory effects of HER4. Therefore, both tyrosine phosphorylation of HER4 and a γ-
secretase-sensitive step appear necessary for HER4 growth inhibition.
Ectopic expression of GFP-s80HER4 and GFP-CTHER4
Because γ-secretase mediates release of s80HER4, and because inhibition of γ-secretase
impaired heregulin-mediated growth inhibition, we studied whether s80HER4 could
transduce the HER4 anti-proliferative effects in experiments that used the following
constructs: 1) GFP-CTHER4, which consists of GFP fused at the N-terminus of the HER4
carboxy terminus (residues 989–1308); 2) GFP-s80HER4, GFP fused at the N-terminus of the
entire HER4 cytoplasmic domain (residues 676–1308); and 3) and GFP alone (Fig. 3A
schematic). We chose to place GFP at the N-terminus to avoid fusion to the HER4 C-
terminal PDZ-binding domain, which may play a role in HER4 action. Note that GFP-
CTHER4 lacks the kinase domain. These three constructs were cloned into pMSCV vector
and packaged as retroviruses with VSVG coat proteins to enhance infectivity of epithelial
Feng et al. Page 4













cells. After infection and selection of pooled clones of stably transfected cells with
puromycin, the level of expression was determined by immunoblotting SUM44 cell lysates
with GFP antibody (Fig. 3B). GFP was expressed at high levels; GFP-CTHER4 and GFP-
s80HER4 were expressed at lower but similar levels. Immunoprecipitation of HER4 with a
polyclonal antibody directed at the HER4 C-Terminus, followed by immunoblotting with
anti-phosphotyrosine antibody, demonstrated that GFP-s80HER4 was constitutively tyrosine
phosphorylated, whereas GFP-CTHER4 was not (Fig. 3C). Carpenter has also recently
reported that s80HER4 is constitutively tyrosine phosphorylated, and can homodimerize (49).
Next, we determined whether expression of the three constructs altered the ligand-
independent or ligand-dependent phosphorylation of HER2, HER3, and HER4. In the
absence of heregulin, there was little to no basal tyrosine phosphorylation of the three
endogenous full-length receptors. Addition of heregulin induced tyrosine phosphorylation of
full-length HER2, HER3, and HER4 in cells expressing GFP-s80HER4, GFP-CTHER4, or
GFP (Fig. 3C). Thus, the phosphorylation level of the cell surface, transmembrane HER4 is
not altered by expression of either the constitutively tyrosine phosphorylated, presumably
dimeric, kinase active GFP-s80HER4 or GFP-CTHER4, which lacks the kinase domain.
Figure 3C shows that membrane HER2, HER3, and HER4 are expressed and ligand-
dependent tyrosine phosphorylated at roughly similar levels. The protein level of s80HER4
and GFP-CTHER4 are somewhat greater than endogenous HER4. CT is not phosphorylated,
but s80HER4 is constitutively tyrosine phosphorylated at levels slightly less than that of
ligand activated endogenous 180kDa HER4. This indicates that the s80HER4 kinase is less
active or less efficiently dimerized in this cellular contest. More importantly, Figure 3
demonstrates that in these stably tranfected cell lines, s80HER4 is not functionally
overexpressed and that the biologic effects described below do not result from substantial
overexpression of exogenous s80HER4 kinase.
We made five distinct breast cell lines stably expressing GFP-CTHER4 or GFP-s80HER4 to
test the ability of s80HER4 and the HER4 C-terminus (without kinase) to alter growth.
Having demonstrated that GW572016 can inhibit HER4 in SUM44, we used the mouse
mammary immortalized but non-neoplastic cell line, HC11, to determine if GW572016
could inhibit heregulin-dependent, full-length HER4 tyrosine phosphorylation and s80HER4
constitutive tyrosine phosphorylation. GW572016 inhibited both full-length HER4 and
s80HER4 tyrosine phosphorylation in a similar dose dependent manner (Fig. 3D). To confirm
this, we expressed both HER4 and s80HER4 at similar level by transient expression in COS-7
cells and examined the relative Ki inhibition by GW572016. The results showed that full
length HER4 and s80HER4 were similarly inhibited by this pan-EGFR family inhibitor (Fig.
3E).
Subcellular localization of GFP, GFP-CTHER4 and GFP-s80HER4
The localization of GFP, GFP-CTHER4 and GFP-s80HER4 was examined using both live cell
(GFP) and fixed cell analysis. Using live cell microscopy (Fig. 4A), it was observed that
GFP and GFP-CTHER4 were distributed in cytoplasm and nuclei of HC11 cells, whereas
GFP-s80HER4 was more concentrated in nuclei. Confocal microscopy (Fig. 4B) confirmed
that GFP-s80HER4 was strongly localized to nuclei whereas GFP and GFP-CTHER4 were
distributed between the cytoplasm and nuclei. Addition of leptomycin B, an antibiotic that
slows nuclear export, to HC11 enhanced GFP-CTHER4 nuclear localization; GFP-s80HER4
was principally nuclear in the presence or absence of leptomycin B in HC11 cells.
We performed similar analyses in GFP, GFP-CTHER4, and GFP-s80HER4 expressing
SUM44 cells. Live cell microscopy of SUM44 cells expressing these constructs
demonstrated that both GFP and GFP-CTHER4 appeared to be nearly equally distributed
between the nucleus and cytoplasm. In contrast, GFP-s80HER4 accumulated to a greater
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degree in SUM44 cell nuclei (supplementary Fig. 1A). Live cells show the variability of
expression levels in the cell populations, especially in the GFP-CTHER4 and GFP-s80HER4
cell lines, even though all cells are maintained in puromycin to continue selective pressure.
Examination of fixed SUM44 cells, using confocal microscopy (supplementary Fig. 1B)
showed again that GFP and GFP-CTHER4 are diffusely distributed in the cytoplasmic and
nuclear compartments, whereas GFP-s80HER4 is more intensely localized in nuclei. With the
addition of leptomycin B, GFP-CTHER4 is more concentrated in SUM44 nuclei, while GFP-
s80HER4 is again maintained in nuclei (supplementary Fig. 1B).
The results in HC11 and SUM44 cells indicate that GFP-s80HER4 is more often found in the
nucleus than GFP or GFP-CTHER4, either by increased nuclear import or decreased nuclear
export. It is clear that GFP-s80HER4 is not always nuclear, indicating that there are other
processes that regulate this transport. In this study, we observed that overexpression of
s80HER4 caused a change in cell shape in monolayer cultures of both SUM44 and HC11
cells; the mechanism for this change is unknown. In a previous study, we demonstrated that
in 3D matrigel culture, s80HER4 has profound effects on shape and lumen formation,
presumably by sending differentiation signals (50).
Effects of s80HER4 kinase activity to nuclear localization and STAT5A activity
To determine if the s80HER4 tyrosine kinase activity affects nuclear-cytoplasmic shuttling of
s80HER4, we incubated HC11 GFP-s80HER4 cells without or with 0.5 μM GW572016, a
dose that does not abolish s80HER4 tyrosine phosphorylation, or with 5 μM GW572016, a
dose sufficient to substantially reduce s80HER4 tyrosine phosphorylation (see Figs. 3D and
3E). As shown in Fig. 5A, 0.5 μM GW572016 did not affect the localization of GFP-
s80HER4, but 5 μM GW572016 dramatically reduced the nuclear accumulation of GFP-
s80HER4, resulting in cytoplasmic accumulation. To test the specificity of GW572016
inhibition of nuclear localization, COS-7 cells were transfected with GFP-s80HER4, p53-
GFP, or GFP-histone, then treated without or with 10 μM GW572016 for 24 h. Again, as
shown in Fig. 5B, 10 μM GW572016 greatly reduced the nuclear localization of GFP-
s80HER4, but had no effect on the nuclear localization of p53-GFP or GFP-histone (0.5 μM
GW572016 did not affect the nuclear localization of GFP-s80HER4 in COS-7 cells, data not
shown). Whether GW572016 has other effects (other than HER4 tyrosine kinase inhibition)
that regulate nuclear localization cannot be ruled out, but recent analyses showed that
GW572016 is highly specific for the ErbB family (51) and the doses used do not alter the
nuclear localization of p53 or histone.
It has been reported that: i) HER4 and STAT5A are essential for breast development and
lactation (9,32), ii) HER4 and STAT5A co-immunoprecipitate (52), and iii) s80HER4 and
STAT5A co-localize in nuclei (50,53). We determined if GW572016 inhibition affected the
co-immunoprecipitation of GFP-s80HER4 and STAT5A in co-transfected cells, and if
GW572016 affected STAT5A tyrosine phosphorylation and nuclear localization. Fig. 6A
shows that GFP-CTHER4 did not associate with STAT5A, while GFP-s80HER4 did. 5 μM
and 10 μM GW572016 greatly decreased the tyrosine phosphorylation of GFP-s80HER4, and
resulted in the decrease of the co-immunoprecipitation of GFP-s80HER4 and STAT5A.
Furthermore, 5 μM and 10 μM GW572016 decreased s80HER4 and STAT5A tyrosine
phosphorylation (Fig. 6B), while 0.5 μM GW572016 did not. Lastly, 5 μM GW572016
decreased nuclear localization of STAT5A in HC11 s80HER4 expressing cells (0.5 μM
GW572016 did not alter nuclear STAT5A localization, data not shown). These results
indicate that s80HER4 kinase activity can regulate STAT5A localization. As can be seen in
Figure 3E, 5 μM GW572016 decreases GFP-s80HER4 expression minimally, but the
decrement in tyrosine phosphorylation, and thus STAT5A nuclear localization, is much
greater. When 10 μM GW572016 is used, s80HER4 expression is suppressed by ~25%, but
tyrosine phosphorylation is almost totally abolished. Thus, GW572016 at high doses may
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have off-target effects, but the kinase inhibition and STAT5A changes are seen at doses
below this.
Biologic action of GFP-s80HER4; growth inhibition of multiple breast cell lines
The majority of our studies have been performed in the SUM44 cell line, which exhibits a
higher HER4 expression level than most breast cancer lines. In our previously published
survey, SUM44 had the most robust heregulin-dependent growth inhibition of human breast
cell lines tested (31). Having shown in Figures 1 and 2 that pharmacologic inhibition of γ-
secretase and HER4 tyrosine kinase activity abrogated heregulin-dependent growth
inhibition, we determined whether constitutive expression of s80HER4 would result in
ligand-independent growth inhibition. First, a time course of cell growth using SUM44 cells
stably expressing GFP, GFP-CTHER4 and GFP-s80HER4 showed slower growth of SUM44
s80HER4 cells at 7 days (Fig. 7A). Multiple replicates of this experiment demonstrated that
constitutive GFP-s80HER4 expression resulted in a statistically significant 50%, decrease in
growth rate, compared to cells expressing GFP and GFP-CTHER4 (Fig. 7B). The extent of
growth inhibition was similar to that seen with the addition of heregulin to parental SUM44
cells (Fig. 1 and ref. (31)). To determine if this effect was limited to SUM44 cells, we stably
expressed GFP, GFP-CTHER4 and GFP-s80HER4 in the following lines: MDA-MB-453 and
SUM102 cells; both of which are human breast cancer cell lines with low-level or absent
HER4 expression, respectively; a non-transformed human mammary cell line, MCF10A;
and the non-transformed mouse mammary epithelial cell line, HC11. Figure 7C shows cell
growth comparisons for each line, stably expressing GFP, GFP-CTHER4 or GFP-s80HER4. In
each instance, growth rates in GFP and GFP-CTHER4 were similar; expression of GFP-
s80HER4 reduced growth by approximately 50%. Thus, the tyrosine kinase domain-bearing
s80HER4 mimics growth inhibition observed with heregulin treatment in HER4-expressing
cells.
The anti-proliferative effects of GFP-s80HER4 were not caused by excess apoptosis
Data of others suggest that transient transfection of s80HER4 result in decreased cell number
by inducing caspace activity and apoptosis (54). We measured apoptosis in several cell lines
in which stable expression of s80HER4 reduced cell number during 3–7 day growth
experiments. SUM44 cells stably expressing GFP, GFP-CTHER4, or GFP-s80HER4 were
cultured for six days in serum-free growth factor-defined media, trypsinized, and equal cell
numbers were used to detect histone-associated DNA fragment (apoptosis) using a sensitive
ELISA assay. No statistically significant differences were detected in apoptosis rates
between GFP, GFP-CTHER4, or GFP-s80HER4 cells. As a positive control, GFP-expressing
cells were treated with 1.0 μM camptothecin for the final 24 hours of the culture.
Camptothecin increased apoptosis by nine-fold (Fig. 8A). Similarly, HC11 cells, stably
expressing GFP, GFP-CTHER4, or GFP-s80HER4, were plated and cultured in complete
medium for one day, and then replaced with serum-free growth factor-defined medium and
cultured for two days. Then the cells were trypsinized and equal cell numbers were used to
detect apoptosis. No difference in apoptotic rates was detected between the three HC11
lines. Camptothecin treatment again dramatically increased apoptosis in GFP-HC11 cells
(Fig. 8B). In both experiments, equal cell numbers were used, even though GFP-s80HER4
cells grew at half the rate, and the equal cell number represented a larger proportion of the
culture. Still, rates of apoptosis were the same, suggesting that the expression of s80HER4
inhibits cell number increase by mechanisms other than stimulating apoptosis. Other
experiments using cell lines stably or inducibly expressing s80HER4 have failed to show sub
2N DNA content on cell cycle analyses (45) or positive tunnel assays.
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GFP-s80HER4, but not GFP-CTHER4, stimulates β-casein promoter activity and protein
expression
Previous reports demonstrate that CTHER4, when fused to the GAL4 DNA binding domain,
transactivated a GAL4 reporter system (25) (42). Data from other groups have shown that a
similar C-terminal construct from EGFR and HER2 also transactivated the GAL4 promoter
(43,44). Recently, work showed that HER4, transfected with STAT5A, stimulated β-casein
promoter activity in MCF7B cells (53). In other work, we have demonstrated ligand- and
HER4-dependent β-casein transcription is abrogated by preventing HER4 cleavage and
s80HER4 production (50). To determine if promoter activation is stimulated by CTHER4 or
s80HER4, we transiently co-transfected parental HC11 cells with plasmids containing GFP,
GFP-CTHER4, or GFP-s80HER4, and pβ casein-lux, a reporter construct used to detect
STAT5A-dependent gene expression (50), or pGL3 vector without β–casein promoter as
control. While co-transfection with GFP or GFP-CTHER4 produced similar β-casein
promoter activity, co-transfection with GFP-s80HER4 increased luciferase transcription from
the β-casein promoter (Fig. 9A). This indicates (using a mammary-specific promoter
system) that the entire HER4 cytoplasmic domain is more effective than the HER4 C-
terminus at increasing transactivation. We next checked the β-casein mRNA levels in HC11
cells stably expressing GFP, GFP-CTHER4, or GFP-s80HER4 using quantitative reverse
transcription-PCR (qRT-PCR). In the basal state, β-casein mRNA level in GFP-s80HER4
expressing cells was more than five-fold above that in GFP or GFP-CTHER4 expressing
cells. Addition of 5 μg/ml of prolactin resulted in huge increases in all the HC11 cells, but
GFP-s80HER4 expressing cells still produced approximately two-fold more β-casein mRNA
above that seen in GFP or GFP-CTHER4 expressing cells (Fig. 9B). Lastly, we showed that
prolactin-stimulated β–casein protein expression was greater in HC11 cells stably expressing
GFP-s80HER4 (Fig. 9C). The effect of tyrosine kinase active s80HER4 on STAT5A dynamics
and on β-casein expression strongly suggests a role for s80HER4 in the events regulation of
mammary cell differentiation.
DISCUSSION
The EGF receptor has been studied as the prototype for receptor tyrosine kinase proliferative
signaling. The discovery that HER2/neu, the second member of the family, could be mutated
to cause experimental carcinogenesis and was overexpressed in almost 20% of human breast
cancers reinforced the idea that ErbB receptors regulate proliferation and, when activated,
oncogenic progression. HER3/ErbB3 is often co-expressed with HER2 in human breast
cancers and is implicated in proliferation and survival signaling.
HER4 is the one family member that has been associated with growth inhibition in many,
but not all, cell culture models. We and others have used breast cancer cell lines under
serum-free conditions to show that ligand-dependent activation of endogenous HER4 results
in growth inhibition (32, (25) and, in responsive cells, a differentiation signal defined by the
transcription of lactation genes (52). Our new results confirm the ability of HER4 to inhibit
growth of breast cancer cells, and demonstrate that the intracellular domain of HER4,
s80HER4, is sufficient to confer growth inhibition to a wide range of breast cells. However,
there are examples in which ectopic expression or activation of HER4 results in a
proliferative rather than a growth inhibitory response (37,55); these have generally used
non-breast cell models or an alternative, spliced cytoplasmic HER4 isoform (Cyt2).
Answers to the conundrum of differential HER4 responses in different cell types is
beginning to emerge, with several discoveries. The first (by Elenius and co-workers)
demonstrated multiple HER4 isoforms, resulting from alternative splicing in two regions,
the extracellular juxtamembrane region (JM-a and JM-b) and a C-terminal insert region,
CYT-1 (versus CYT-2), that changes signaling capabilities (19–21). The second discovery
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(by Carpenter’s and Kim’s groups) was the finding that the JM-a isoform, which contains a
TACE cleavage site (22,23), was susceptible to a second γ-secretase cleavage (1,2). Our
interest in HER4-dependent growth inhibition prompted us to look at the role of s80HER4 in
that process.
Carpenter’s original report suggested that T47D growth could be inhibited by the heregulin-
induced production of s80HER4, and that the nuclear localization and nuclear export
sequences, found uniquely in HER4 among members of the EGF receptor family, could
bring s80HER4 to the nucleus (25). Jones and co-workers showed that this translocation may
result in co-translocation of STAT5A with s80HER4 into the nucleus, with potential
consequences for STAT5A-inducible genes (53). Additionally, a HER4 C-terminus fusion
protein, lacking the tyrosine kinase domain, was capable of transactivating a GAL4
promoter construct in co-transfection studies (25,42). This is parallel to findings that a
similar amino acid region in the C-terminus of both EGF receptor and HER2 can likewise
transactivate GAL4 in co-transfection assays (43,44). It has been speculated that s80HER4
might be cleaved in the nucleus to yield a transactivating product without the tyrosine kinase
domain (56).
Our current work extends these recent results, first by using the SUM44 cell, our major
model of heregulin and HB-EGF-dependent growth inhibition, to show that γ-secretase
inhibition blocks the HER4 anti-proliferative effect. Likewise, we show that inhibition of the
tyrosine kinase activity, by GW572016, also blocks the anti-proliferative effects. The
blockade of heregulin-dependent HER4 tyrosine phosphorylation (e.g. in Figs. 2 and 3)
could inhibit signaling, either by blocking surface HER4 signaling or by inhibiting the
production of s80HER4 by TACE, and γ-secretase. While additional experiments are needed,
our data suggest that s80HER4 can recapitulate ligand-dependent HER4 growth inhibition
(Figs. 1, 2 and 7). However, at physiologic ligand and receptor levels, HER4-dependent
growth inhibition may require both the production and action of s80HER4, as well as
sustained HER4 cell surface tyrosine kinase activity.
Our data show that s80HER4 translocated and accumulated in the nucleus, in both live and
fixed cells. We note that s80HER4 was not predominantly in the nucleus of every cell in
which it was expressed, suggesting that there are complex mechanisms governing s80HER4
nuclear translocation. Tyrosine kinase activity appears to be at least one regulatory
component, as GW572016 inhibition of s80HER4 constitutive tyrosine kinase activity
dramatically impaired s80HER4’s nuclear accumulation. This constitutive ligand-
independent, transmembrane HER4-independent, s80HER4 tyrosine phosphorylation
indicates that the GFP-s80HER4 fusion protein has tyrosine kinase activity, a finding recently
confirmed by others (49). We have confirmed the importance of s80HER4 tyrosine kinase
activity in nuclear localization by showing the site-directed mutant s80HER4 lacking kinase
activity also fails to localize in HC11 nuclei (50).
Lastly, our data indicate that s80HER4 inhibits growth and can enhance a STAT5-mediated
transcription process to a greater extent than the HER4 C-terminal fragment. In five
different breast/mammary cell lines, the expression of s80HER4, but not CTHER4, resulted in
substantial growth inhibition. Growth inhibition under the conditions tested was not due to
increased apoptosis. While published data suggests specific sequences within the
cytoplasmic domain of HER4 can activate caspaces and apoptosis (54), our data indicate
that chronic s80HER4 expression results in slower growth, without increasing apoptosis.
Transactivation by the HER4 C-terminus, and other EGF receptor family C-termini, has
been shown by several groups, using a GAL4 promoter transactivation assay (25,42). Our
data indicate that the mammary gland β-casein promoter is not effectively transactivated by
CTHER4, whereas s80HER4, presumably in concert with STAT5A, can produce at least
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modest transactivation in this co-tranfection assay. Taken together, our results suggest that
s80HER4, rather than CTHER4, is the biologically relevant entity in breast cells.
We do not know how growth inhibition or differentiated gene expression is regulated by
s80HER4, but evidence is accumulating that HER4 is a uniquely endowed receptor tyrosine
kinase, one in which precisely regulated proteolysis releases the cytoplasmic domain with an
intact kinase activity. The encoded nuclear localization and export sequences are unique for
the EGF receptor family and result in cytoplasmic nuclear shuttling with the nuclear
localization appearing to depend upon an active kinase. The released cytoplasmic kinase
domain is capable of continuous autophosphorylation, presumably until some
physiologically relevant process turns it off or destroys s80HER4. The localization gives an
indication that signals important to a cell’s fate, growth inhibition, and differentiation are
played out in the cell nucleus. Future challenges include understanding the consequences of
s80HER4 in human breast cancers where it is detected in a number of cases and appears to
correlate with good prognosis tumors.
MATERIALS AND METHODS
Cell lines and cell culture
SUM44 and SUM102 cells were grown in serum-free growth factor-defined media as
previously described (31). MDA-MB-453 cells and MCF10A cells were obtained from
American Type Culture Collection (Manassas, VA). MDA-MB-453 and COS-7 cells were
grown in Dulbecco modified Eagle Medium (Gibco BRL) supplemented with 10% fetal
bovine serum (FBS). HC11 cells were grown in RPMI1640 with 10% FBS plus 5 μg/ml
insulin (Gibco BRL), 10 ng/ml EGF (BD Biosciences, Bedford, MA) and antibiotics in a
humidified incubator at 37°C with 5% CO2. All other cells were grown in a humidified
incubator at 37°C with 10% CO2. Recombinant heregulin β1 was a gift from Genentech.
Hydroxyethylene dihydropeptide isostere (HEDI) and prolactin were obtained from Sigma-
Aldrich, St. Louis, MO.
Cell Growth Assay
Heregulin and inhibitor effects on SUM44 cells were evaluated by counting cells via
hemacytometer as previously described (31). The cell growth assays in Fig. 7 were
performed as following. 5,000 cells/well were plated in a 96 well plate, and cultured in
serum-free growth factor-defined media at 37°C with 10% CO2. Cell number was analyzed
using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] assay [CellTiter 96 Aqueous nonradioactive cell-
proliferation assay kit (Promega)] according to manufacturer’s directions. Percentage
increase = 100 × (ODend − OD20h)/OD20h.
Plasmid construction and transfection
The expression construct pLXSN-HER4 encoding full-length human HER4 (31) and pEGFP
(Clontech) were used as templates for PCR amplification using Pfu DNA polymerase
(Stratagene) to make constructs of GFP-CTHER4 (HER4 residues 989–1308) and GFP-
s80HER4 (HER4 residues 676–1308) (Figure 3A). Both constructs were made by two
overlapping PCRs. The primers generating GFP-CTHER4 were as following: 5′ GFP,
cggggtaccatggtgagcaagggcgaggag; 3′ GFP, aagcttcatacgatcatcacccttgtacagctcgtccatgcc; 5′
CT, ggcatggacgagctgtacaagggtgatgatcgtatgaagc; 3′ CT, cggggtaccttacaccacagtattcc. The
PCR products initially subcloned into pCDNA3 vector (Invitrogen), then subcloned into
pMSCVpuro vector (Clontech). The primers generating GFP-s80HER4 were: 5′ GFP,
ggaagatctgtcgccaccatggtgagcaagggc; 3′ GFP, ctttttgatgctcttccttctagtccggccggacttgtacag; 5′
s80HER4, ctgtacaagtccggccggactagaaggaagagcatcaaaaagaaaagagc; 3′ s80HER4,
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ttttccttttgcggccgcttacaccacagtattccggtg. The PCR product were subcloned into pMSCVpuro
vector. All constructs were fully verified by DNA sequencing. The plasmid construct
pMSCV-GFP, p53-GFP (57), and pQC-GFP-histone were kindly provided by Drs. Scott
Hammond, Yanping Zhang, and James Bear (UNC Lineberger Comprehensive Cancer
Center), respectively. Transfection was performed using FuGENE 6 (Roche Molecular
Biochemicals) according to the manufacturer’s protocol.
Retrovirus Production, Infection and stable cell lines
A293T cells, seeded one day before at a density of 4–5 × 106 cells in 100-mm plates, were
transfected with a packaging plasmid pCMV-VSVG and pUMVC3-gagpol (both vectors and
A293T cells were kindly provided by Dr. Lishan Su, UNC Lineberger Comprehensive
Cancer Center), and either pMSCV-GFP, pMSCV-GFP-CTHER4 or pMSCV- GFP-s80HER4
using FuGENE 6 (Roche Molecular Biochemicals) according to the manufacturer’s
protocol. Viral supernatants were collected after 60 h of incubation, the last 48 h at 32°C
with DMEM medium plus 2% FBS. Viral supernatants were filtered through a 0.45-μm-
pore-size syringe filter, and were added with 8 μg of polybrene per ml to recipient cells
which had been plated at 7 × 105 cells per 100-mm dish the day before. The cells were
incubated at 37°C for 6 h in the filtered viral supernatant and then changed to normal growth
medium. After 60 h of incubation, cells were selected in medium containing 2 μg/ml
puromycin. Puromycin-resistant cells were pooled, and expression of the cDNA product was
confirmed by western blotting. For the images of live cell microscopy in Fig. 4A and Fig.
5A, GFP positive cells were also selected by Modular Flow Cytometer (Cytomation Inc.).
Immunoprecipitation and immunoblot analysis
Cells were washed with cold phosphate-buffered saline and lysed in regular lysis buffer
containing 20 mM Tris-HCl (pH 7.5), 50 mM sodium fluoride, 10% glycerol, 0.5% NP-40,
1 mM EDTA, 1mM EGTA, 20 mM β-glycerophosphate and 137 mM NaCl supplemented
with sodium orthovanadate (1 mM) and Protease Inhibitors Cocktail (Roche), or high salt
lysis buffer containing 20 mM HEPES, 50 mM NaF, 10% glycerol, 1% Triton, 5 mM
EDTA, 500 mM NaCl, 1 mM sodium orthovanadate and protease inhibitors cocktail.
Insoluble material was removed by centrifugation at 13,000 × g for 10 min at 4°C. Receptor
proteins were precipitated for 3 h or overnight at 4°C with protein A/G or protein A agarose
beads (Santa Cruz Biotechnologies, Santa Cruz, CA) and the following antibodies: HER2
[clone 9G6.10, mouse monoclonal antibody (Neomarkers, Inc.)]; HER3, polyclonal rabbit
antisera raised by this lab against HER3 C-terminal; HER4, polyclonal rabbit antisera raised
by this lab against recombinant gluthathione S-transferase fusion protein containing the C-
terminal 80 amino acids of HER4; STAT5A (Zymed Laboratories). Immune complexes
were washed three times with lysis buffer and denatured in sodium dodecyl sulfate (SDS)
sample buffer. Protein samples were separated on a SDS-8% polyacrylamide gel and were
electrophoretically transferred to a Sequi-blot polyvinylidene difluoride membrane (Bio-
Rad). After blocking with 3% cold fish gelatin (Sigma), the membrane was probed overnight
at 4°C or 1.5 h at room temperature with antiphosphotyrosine antibody (PY20; Santa Cruz
Biotechnologies), HER4 antibody, HER2 antibody (Clone 2F12, Upstate, Lake Placid, NY),
HER3 antibody (Ab-1, NeoMarkers, Fremont, CA), GFP antibody (Chemicon, Temecula,
CA), STAT5A antibody, β-casein antibody (Santa Cruz Biotechnologies) or α–tubulin
antibody (Santa Cruz Biotechnologies), washed three times with 0.1% Tween-20 in Tris-
buffered saline, and detected with Enhanced ChemiLuminescence detection kit (Amersham
Life Sciences).
Microscopy and Image acquisition
The images of live cell microscopy were captured using a Zeiss Axiovert 200 (LD A-Plan
20×/0.30 Ph1), and digitally acquired using a Zeiss AxioCam with Openlab 3.1.4 Zeiss
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imaging software. For fixed cell microscopy, the cells were grown on coverslips fixed in
3.7% formaldehyde, washed with PBS, and stained with DAPI (20 ng/ml), or STAT5A
antibody and rhodamine red-conjugated donkey anti-mouse IgG (Jackson Immuno Research
Laboratories). The coverslips were washed with PBS and mounted onto glass slides in
fluorescent mounting media (DakoCytomation). Cells were visualized using either the Zeiss
Axiovert 200 as above, or the Leica SP2 laser scanning confocal microscope with a 63x oil
NA 1.40 Plan Apo lens (Nikon). For confocal microscopy, excitation of GFP and DAPI was
performed using an argon ion laser at 488 nm and an UV laser at 364 nm respectively.
Images were acquired and processed using Leica Confocal software. Minimal image
processing was performed with Adobe Photoshop.
Apoptosis assay
Cell death was quantified by using the Cell Death Detection ELISA (Roche Molecular
Biochemicals) which detects cytoplasmic histone-associated DNA fragments (mono- or
oligonucleosomes). SUM44 cells stably expressing GFP, GFP-CTHER4 or GFP-s80HER4
were plated in 100 mm plates in serum-free medium changing the medium every other day.
After seven days, the culture medium was saved to collect any floating cells. HC11 cells
stably expressing GFP, GFP-CTHER4 or GFP-s80HER4 were plated in complete medium and
cultured for 1 day, then the medium was replaced with serum-free growth factor-defined
medium and cultured for 2 more days. At the end of the cell culture, the culture medium was
saved to collect any floating cells. The attached cells were trypsinized off the plate and
combined with the saved culture medium. Equal numbers of cells were obtained from each
of the SUM44 or HC11 cells expressing GFP, GFP-CTHER4 or GFP-s80HER4, and then
processed for apoptosis determination following the instructions of the supplier.
Quantitative reverse transcription-PCR (qRT-PCR)
qRT-PCR was performed as described previously (45). Briefly, total RNA was isolated from
HC11 cells stably expressing GFP, GFP-CTHER4, or GFP-s80HER4 by using an RNeasy kit
(QIAGEN) and was treated with RNase-free DNase (Ambion). β-casein primers and
intervening fluorescent dye-labeled probes were designed using Primer Express software
(ABI/Perkin-Elmer). Total RNA (10 ng) isolated from each cell line was assayed by real-
time fluorescence qRT-PCR using an ABI PRISM 7900 instrument (PE Bio). Relative
abundance of β-casein transcript was calculated by the formula: relative mRNA level =
e(40-Ct).
Statistical analysis
Significant differences between treatment groups were assessed by Student’s t-test. P < 0.05
was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The abbreviations used are
s80HER4 soluble 80 kDa HER4 cytoplasmic domain
CTHER4 HER4 C-terminus beyond the tyrosine kinase domain, residues 989–1308
NLS nuclear localization sequence
NES nuclear exporting sequence
STAT5A signal transducer and activator of transcription 5A
TACE tumor necrosis factor-α-converting enzyme
TPA tetradecaonylphorbol-13-acetate
HEDI hydroxyethylene dihydropeptide isostere
DAPI 4′,6-diamidino-2-phenylindole
MAPK mitogen-activated protein kinase
PI3K phosphatidylinositol 3-kinase
VSVG vesicular stomatitis virus glycoprotein
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Fig. 1. Inhibition of γ-secretase blocks heregulin-induced growth inhibition
SUM44 cells grown in fully complemented medium were treated with heregulin (10 ng/ml)
or not in the presence or absence of HEDI at the concentrations shown for 6 days, then
counted. Mean ± SD of triplicates are shown, representative of 3 independent experiments.
Student’s t-test was used for statistical analysis. ***, P < 0.001 versus control.
Feng et al. Page 17













Fig. 2. Inhibition of HER4 tyrosine phosphorylation blocks heregulin-induced growth inhibition
A, SUM44 cells were cultured for 6 days, treated with different doses of GW572016 for 1 h,
and then with or without heregulin (10 ng/ml) for 15 minutes. The cells were lysed and the
lysates were immunoprecipated with anti-HER2, anti-HER3, or anti-HER4 antibody and
blotted with anti-phosphotyrosine antibody. B, SUM44 cells were grown with or without
heregulin (10 ng/ml) in the presence or absence of GW572016 (1 μM) for 6 days, at which
time the number of cells were counted. Mean ± SD of triplicates are shown, representative
of 3 experiments. ***, P < 0.001 versus control.
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Fig. 3. Ectopic expression of GFP-s80HER4 and GFP-CTHER4
A, Schematic representation of full-length HER4, GFP, GFP-CTHER4, and GFP-s80 HER4. B,
Western analysis using anti-GFP antibody of lysates from SUM44 cells infected with
retrovirus encoding GFP, GFP-CTHER4, or GFP-s80HER4. C, SUM44 cells stably expressing
GFP, GFP-CTHER4, or GFP-s80HER4 were treated with or without heregulin (10 ng/ml) for
15 minutes, and lysed. The lysates were immunoprecipated with anti-HER2, anti-HER3, or
anti-HER4 antibody and blotted with anti-HER2, anti-HER3, or anti-HER4 antibody
respectively, or with anti-phosphotyrosine antibody. D, HC11 cells stably expressing GFP,
GFP-CTHER4, or GFP-s80HER4 were treated with ± increasing concentrations of GW572016
for 1 h (top panel), or treated with different concentration of GW572016 for 1 h, then ±
heregulin (10 ng/ml) for 15 minutes (bottom panel), and lysed. The lysates were
immunoprecipated with anti-HER4 antibody and blotted with anti-phosphotyrosine
antibody. E, COS-7 cells were transfected with full-length HER4 or GFP-s80HER4. Twenty-
four h after transfection, the cells were treated with ± increasing concentrations of
GW572016 for 1 h, lysed, and analysed for the level of tyrosine phosphorylation of HER4 or
GFP-s80HER4 by using anti-phosphotyrosine antibody, and the level of HER4 or GFP-
s80HER4 by using anti-HER4 antibody. Densitometry is shown in arbitrary units.
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Fig. 4. Localization of GFP, GFP-CTHER4, and GFP-s80HER4 in HC11 cells
A, Live cell microscopy showing the localization of GFP fluorescence in HC11 cells stably
expressing GFP, GFP-CTHER4, or GFP-s80HER4. Phase contrast is shown in lower panels.
Bar, 100 μm, applies to each image. B, HC11 cells stably expressing GFP (a-c, j-l), GFP-
CTHER4 (d-f, m-o) or GFP-s80HER4 (g-i, p-r), were treated without (a-i), or with (j-r) 20 ng/
ml of leptomycin B for 24 h, then analyzed for GFP fluorescence by confocal microscopy.
Subcellular distribution of GFP (a, j), GFP-CT (d, m), GFP-s80 (g, p), and DAPI (b, e, h, k,
n, q) were visualized and captured. The merged pictures were also shown (c, f, i, l, o, r). Bar,
30 μm, applies to each image.
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Fig. 5. Effect of GW572016 on the localization of GFP-s80HER4 in HC11 cells
A, HC11 cells stably expressing GFP-s80HER4 were treated without, or with 0.5 μM or 5 μM
GW572016 for 24 h. Cells on the cover slip were fixed, stained with DAPI, then analyzed
for GFP and DAPI fluorescence. The merged pictures were also shown. Bar, 30 μm, applies
to each image. B, COS-7 cells were transfected with GFP-s80HER4, p53-GFP, or GFP-
histone, and treated without or with 10 μM GW572016 for 24 h. Then, the cells were fixed,
stained with DAPI, and analyzed for GFP and DAPI fluorescence. The merged pictures were
also shown. Bar, 30 μm, applies to each image.
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Fig. 6. Effect of GW572016 on STAT5A and GFP-s80HER4 co-immunoprecipitation, STAT5A
tyrosine phosphorylation and STAT5A nuclear localization
A, COS-7 cells were co-transfected with STAT5A and GFP-CTHER4 or STAT5A and GFP-
s80HER4, and treated without or with increasing concentrations of GW572016 for 40 hours.
Cells were lysed with regular lysis buffer (137mM NaCl), and lysates immunoprecipitated
with anti-HER4 or anti-STAT5 antibody. Immunoprecipitates were subject to gel
electrophoresis and transferred and blotted with anti-HER4, anti-STAT5, or anti-
phosphotyrosine antibody as indicated. B, COS-7 cells were co-transfected with GFP-
s80HER4 and STAT5A, and treated without or with different concentrations of GW572016
for 40 hours. Cells were lysed in high salt (500 mM NaCl) lysis buffer, and the lysates were
immunoprecipitated with anti-HER4 or anti-STAT5 antibody, electrophoresed, transferred,
and blotted with anti-phosphotyrosine, anti-STAT5 or anti-HER4 antibody. C, HC11 cells
stably expressing GFP-s80HER4 were treated without or with GW572016 (5 μM) for 24 h.
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Cells were fixed and visualized for GFP or rhodamine (using a rhodamine-labeled second
antibody following the first antibody-antiSTAT5). The merged pictures are also shown. Bar,
30 μm, applies to each image.
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Fig. 7. Ectopic expression of GFP-s80HER4, but not GFP-CTHER4, decreases cell proliferation
A, Time course of cell proliferation of SUM44 cells stably expressing GFP, GFP-CTHER4,
or GFP-s80HER4. SUM44 cells (5000 cells per well) stably expressing GFP, GFP-CTHER4,
or GFP-s80HER4 were plated in 96-well plates and cultured. At indicated time points, the
relative cell numbers (OD values) were measured using MTS assay. Percentage increased
OD value at each time point over the 20h time point are shown (Mean ± S.E.M. of
triplicates). B, Cell proliferation of SUM44 cells stably expressing GFP, GFP-CTHER4, or
GFP-s80HER4 after 7 days incubation. The percentages of increased OD value at the end of
the incubation (7 days) to that at 20 hours are shown. The error bar represented S.E.M. of
five independent experiments, each analyzed in triplicate. Student’s t-test was used for
statistical analysis. ***, P < 0.001 versus GFP control. C, MTS assays showing cell
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proliferation of MDA-MB-453, MCF10, HC11 and SUM 102 cells stably expressing GFP,
GFP-CTHER4 or GFP-s80HER4. OD values of the cells stably expressing GFP, GFP-CTHER4
or GFP-s80HER4 were determined at 20h and the end of the cell culture (MDA-MB-453, 5
days; MCF10A, 8 days; HC11, 3 days; SUM102, 4 days) using MTS assay. The percentages
of increased OD value at the end of the incubation to that at 20 h are shown (the error bar
represented S.E.M of triplicate samples). *, P < 0.05; **, P < 0.01 versus GFP control.
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Fig. 8. Stable expression of GFP-s80HER4 does not induce apoptosis
A, SUM44 cells stably expressing GFP, GFP-CTHER4 or GFP-S80HER4 were cultured in
serum-free medium for 7 days. GFP expressing cells were also treated with 1 μM of
camptothecin for 24 h before harvesting the cells as a positive control. Equal cell numbers
were analyzed for apoptosis by ELIZA, which quantitatively measures cytoplasmic histone-
associated DNA fragments. Results are expressed as mean±S.E.M. of three independent
experiments; each sample being analyzed in duplicate. The Student’s t-test was used for
statistical analysis. **, P = 0.006 versus GFP control. B, HC-11 cells stably expressing GFP,
GFP-CTHER4 or GFP-S80HER4 were analyzed for apoptosis after 3 days as described above.
A second plate of GFP expressing cells was treated with 1 μM of camptothecin for the final
24 h of the incubation. **, P = 0.04 versus GFP control.
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Fig. 9. GFP-s80HER4, but not GFP-CTHER4, activates β–casein promoter and increases β–casein
mRNA and protein expression
A, HC11 cells transfected with plasmids containing GFP, GFP-CTHER4 or GFP-S80HER4,
and pβcasein-lux, a reporter construct in which a human β–casein promoter was fused to the
upstream of luciferase reporter gene, or pGL3 vector without β–casein promoter, were lysed
48 h after transfection. The lysates were immunoprecipitated with anti-HER4 antibody and
blotted with anti-phosphotyrosine antibody, and anti-HER4 antibody (top panel). The lysates
from above were also used to determine luciferase activity by luciferase assay system
(Promega). Results are expressed as mean±S.E.M. of three independent experiments with
each sample being analyzed in duplicate (bottom panel). The Student’s t-test was used for
statistical analysis. ***, P < 0.001 versus GFP control or GFP-CTHER4. B, β–casein mRNA
levels as determined by quantitative reverse transcription-PCR (qRT-PCR). HC11 cells
stably expressing GFP, GFP-CTHER4, or GFP-s80HER4 were cultured in normal culture
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medium for 2 days, changed to serum-free complemented medium containing 5 μg/ml
insulin for 2 days, then treated with or without 5 μg/ml prolactin in the complemented
medium for 2 days. Total RNA was extracted and qRT-PCR was performed using β–casein
specific fluorescence-labeled oligonucleotide probes (the error bar represented S.E.M of
triplicate samples). **, P ≤ 0.01 versus GFP control. C, HC11 cells stably expressing GFP,
GFP-CTHER4, or GFP-s80HER4 were cultured as above, and treated with or without 5 μg/ml
prolactin in the complemented medium for 2 days. The cells were lysed and the lysates were
immuno-blotted with anti-β-casein or anti-α-tubulin antibody.
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